Delocamten

Delocamten
Clinical data
Other names	MYK-224; BMS-986435
Identifiers
	IUPAC name (6S,7S)-6-Fluoro-7-(2-fluoro-5-methylphenyl)-3-(oxan-4-yl)-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidine-2,4-dione;
CAS Number	2417411-02-8;
PubChem CID	146586175;
ChemSpider	129910026;
UNII	IE5886BN8T;
KEGG	D12949;
Chemical and physical data
Formula	C19H21F2N3O3
Molar mass	377.392 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C=C1)F)[C@H]2[C@H](CC3=C(N2)NC(=O)N(C3=O)C4CCOCC4)F;
	InChI InChI=1S/C19H21F2N3O3/c1-10-2-3-14(20)12(8-10)16-15(21)9-13-17(22-16)23-19(26)24(18(13)25)11-4-6-27-7-5-11/h2-3,8,11,15-16,22H,4-7,9H2,1H3,(H,23,26)/t15-,16-/m0/s1; Key:NPPSFOUMKWFJKX-HOTGVXAUSA-N;

Delocamten (development code MYK-224) is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy.^[1]^[2]^[3]

References

^ Lehman, Sarah J.; Crocini, Claudia; Leinwand, Leslie A. (June 2022). "Targeting the sarcomere in inherited cardiomyopathies". Nature Reviews Cardiology. 19 (6): 353–363. doi:10.1038/s41569-022-00682-0. ISSN 1759-5010. PMC 9119933. PMID 35304599.
^ Sebastian, Sneha Annie; Padda, Inderbir; Lehr, Eric J.; Johal, Gurpreet (September 2023). "Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy". American Journal of Cardiovascular Drugs. 23 (5): 519–532. doi:10.1007/s40256-023-00599-0. PMID 37526885. S2CID 260348901.
^ Packard, Elizabeth; de Feria, Alejandro; Peshin, Supriya; Reza, Nosheen; Owens, Anjali Tiku (December 2022). "Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy". Cardiology and Therapy. 11 (4): 491–507. doi:10.1007/s40119-022-00283-5. PMC 9652179. PMID 36243823.